skip to main content
Close Icon We use cookies to improve your website experience.  To learn about our use of cookies and how you can manage your cookie settings, please see our Cookie Policy.  By continuing to use the website, you consent to our use of cookies.
Global Search Configuration
asgct_banner2

We’re excited to share our latest report on gene, cell, and RNA therapies with The American Society of Gene and Cell Therapy (ASGCT). This Q2 report calls out important updates and changes within the gene, cell, and RNA therapy landscape.


Highlights of the report include:


Approved gene, cell, and RNA therapies

  • Globally for clinical use, there are:
    • 19 gene therapies approved (including genetically modified cell therapies)
      • No new gene therapies were approved since Q1 2022
    • 18 RNA therapies approved
    • 59 non-genetically modified cell therapies approved

 

Pipeline of gene,cell, and RNA therapies 

  • 3,633 therapies are in development, ranging from preclinical through pre-registration
    • 2,024 gene therapies (including genetically-modified cell therapies such as CAR T-cell therapies) are in development, accounting for 55% of gene, cell, and RNA therapies
    • 803 non-genetically modified cell therapies are in development, accounting for 22% of gene, cell, and RNA therapies

 

Activity including deal-making, start-up financing, noteworthy events, and upcoming catalysts for gene, cell, and RNA therapies

 




Report Contributors

Practice Lead

Ly Nguyen-Jatkoe, PhD

Executive Director, Pharma Custom Intelligence
Ly

Ly Specialises in

  • Competitive Intelligence
  • Business Development and Licensing
  • Product Launch and Commercial Strategy

21+ years of experience

Consultant

Amanda Micklus

Senior Pharma Consultant

Connecticut , USA

Amanda Micklus_Pharma_Intelligence

Amanda Specialises in

  • Business Development and Licensing
  • Market intelligence
  • Primary market research

22+ years of experience

Consultant

Shardha Millington

Consultant, Pharma Custom Intelligence
Shardha Millington

Shardha Specialises in

  • Market intelligence
  • Drug development
  • Research and Development
  • Competitive Intelligence

Previous Reports